Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Lilly Becher : Auswahlbibliographie
View through CrossRef
Die Bibliographie stützt sich auf Angaben in Rolf Harders Korpus-Biographie "Lilly Korpus, verheiratete Becher. Biographische Notizen" (Gransee: Edition Schwarzdruck 2017, S. 45–47) sowie auf die in zwei Bänden erschienene analytische Bibliographie "Internationale Literatur: Moskau 1931 - 1945", bearbeitet von Christa Streller und Volker Riedel (Berlin und Weimar: Aufbau-Verlag 1985).
Title: Lilly Becher : Auswahlbibliographie
Description:
Die Bibliographie stützt sich auf Angaben in Rolf Harders Korpus-Biographie "Lilly Korpus, verheiratete Becher.
Biographische Notizen" (Gransee: Edition Schwarzdruck 2017, S.
45–47) sowie auf die in zwei Bänden erschienene analytische Bibliographie "Internationale Literatur: Moskau 1931 - 1945", bearbeitet von Christa Streller und Volker Riedel (Berlin und Weimar: Aufbau-Verlag 1985).
Related Results
714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism
714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism
Tirzepatide (TZP) , a novel GIP-GLP-1 dual agonist, improved fasting measures of insulin sensitivity partially attributable to weight loss in Phase 2 studies. Studies in mice demon...
P0672 Persistence of Vedolizumab after switching to the subcutaneous route: results from the national French cohort study DOPER
P0672 Persistence of Vedolizumab after switching to the subcutaneous route: results from the national French cohort study DOPER
Abstract
Background
Vedolizumab (VDZ) has been available in France as a subcutaneous formulation for the treatment of inf...
105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial
105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial
Background: InRange has previously demonstrated that insulin glargine 300 U/mL (Gla-300) is non-inferior to insulin degludec 100 U/mL (IDeg-100) in terms of time in glucose range 7...
333-OR: Oxyntomodulin Analog LY3305677 (LY) Improves Glycemic Control and Weight Loss in Healthy Volunteers and Subjects with Type 2 Diabetes (T2D)
333-OR: Oxyntomodulin Analog LY3305677 (LY) Improves Glycemic Control and Weight Loss in Healthy Volunteers and Subjects with Type 2 Diabetes (T2D)
LY is an acylated peptide analog of oxyntomodulin, a dual glucagon and GLP-1 receptor agonist. We conducted 2 randomized, double-blind, phase 1 multiple ascending subcutaneous dosi...
30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
Insulin in T2D is associated with hypoglycemia and weight gain, requires training, can be expensive, and is generally not preferred by patients. Reducing insulin needs is attractiv...
Ulrich Becher
Ulrich Becher
Als "ein Buch wie ein Raumschiff, in dem man aufbrechen kann in wahnwitzige, urkomische und höchst bedrohliche Welten" bezeichnete Eva Menasse Ulrich Bechers Roman "Murmeljagd". Ul...
1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans
1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans
Fibroblast growth factor 21 (FGF21) is a liver-secreted peptide hormone reportedly improving metabolic homeostasis, partly via reduced hunger for sugar, fat, protein and alcohol. E...
743-P: Effect of Once-Weekly TZP on Glycemic Control by Baseline Age in Patient Subpopulations from the SURPASS Trials
743-P: Effect of Once-Weekly TZP on Glycemic Control by Baseline Age in Patient Subpopulations from the SURPASS Trials
Tirzepatide (TZP) is a dual GIP and GLP-1 receptor agonist developed for the treatment of patients with type 2 diabetes (T2D) . The SURPASS clinical trials demonstrated efficacy an...